AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04588363 — intervention group
Intervention type: OTHER
Intervention: SARS-CoV-2 and/or MIS-C Exposure
Description: This is an observational cohort study.
Study NCT02568254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 1 (etafilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Study NCT02568254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 2 (nelfilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Study NCT02568254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens 3 (nesofilcon A)
Description: Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Study NCT01253356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IABP
Description: Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
Study NCT04375215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective caries removal
Description: After caries removal restoration of tooth will be performed
Study NCT04375215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise caries removal
Description: After caries removal restoration of tooth will be performed
Study NCT03456297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based clinical pedagogy program (WCP)
Description: The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
Study NCT01565694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral suspension administered once a day via syringe.
Study NCT03511209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI plus taper method A
Description: This intervention includes CBTI plus the novel hypnotic tapering method.
Study NCT03511209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI plus taper method B
Description: This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
Study NCT01787903 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Real-time continuous glucose monitor
Description: Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
Study NCT01787903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time continuous glucose monitor
Description: Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
Study NCT04901052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 supplementation group
Description: n-3 supplementation group (1.5g of omega 3)
Study NCT04901052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group (sunflower oil)
Study NCT02857920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7.5 mg/kg, i.v, once every 3 weeks (continuous)
Study NCT02857920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg, i.v, once every 3 weeks (continuous)
Study NCT02857920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
Study NCT01778985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin
Study NCT01778985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00723944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Certain Prevail
Description: Root form titanium dental implant
Study NCT00723944 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Osseotite Certain
Description: Dental implant without the lateralized design
Study NCT01382407 — intervention group
Intervention type: DRUG
Intervention: Cetuximab
Description: Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
Study NCT01446588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Three yoga classes per week for 8 weeks.
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: At a dose of at least 5 mg/day.
Study NCT00284934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: At a dose of at least 5 mg/day.
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: albumin-binding prodrug of doxorubicin HCl
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03554109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin HCL
Description: Doxorubicin HCL
Study NCT03554109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel
Study NCT04568772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet
Study NCT04568772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil 250/100 mg
Description: Atovaquone / Proguanil 250/100 mg tablet
Study NCT04568772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet
Study NCT04568772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg tablet
Study NCT04568772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Description: Vonoprazan 20 mg tablet
Study NCT00977184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 HZ Repetitive TMS
Study NCT00977184 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study NCT03057327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve awareness of checking moles
Description: Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant.
Study NCT03057327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
Study NCT00355550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study NCT00355550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study NCT05669066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful meditation
Description: Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
Study NCT02726269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLA (Clarithro+Lanso+Amoxi)
Description: Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
Study NCT02726269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLA (Panto+Levoflox+Azithro)
Description: Tablets of oral administration to subjects randomized to this group once daily for 10 days.
Study NCT00496327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live (Oka-Merck)
Description: VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
Study NCT00801268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii
Description: TW，60mg/d
Study NCT00801268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emodin
Description: 100mg/d
Study NCT01192360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase contrast flow velocity mapping (PC)
Description: An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
Study NCT01192360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Description: Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
Study NCT03274349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body electromyostimulation exercise
Description: whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
Study NCT03274349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protein-rich nutrition therapy
Description: protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
Study NCT03274349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protein-rich nutrition therapy
Description: protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
Study NCT01521364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Addition of different doses of clarithromycin.
Description: At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks.
Study NCT02175758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily
Study NCT01497587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose, 0.5 U/kg, administered s.c. (under the skin)
Study NCT03763435 — intervention group
Intervention type: BEHAVIORAL
Intervention: Antenatal pregnancy classes
Description: At least three comprehensive full-day educational program covering all the stages of pregnancy.
Study NCT00672984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immediate release guanfacine hydrochloride
Description: Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
Study NCT00672984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
Study NCT00672984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
Study NCT00746421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: oral doses, 200 mg, 300 mg, 400 mg
Study NCT00746421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg, 300mg or 400mg
Study NCT00787553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin
Description: 2.0 g, IV, 2 hours before surgery
Study NCT00787553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: 2.0 g orally, 12 hours before surgery
Study NCT02175758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
Study NCT00787553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin plus tinidazole
Description: cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
Study NCT02380976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination drug: DW330SR, DW1030
Study NCT02380976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW340
Study NCT04373083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered in 3-week intervals
Study NCT04373083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-site radiotherapy (IS-RT)
Description: Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
Study NCT01137435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined
Description: 0.5 mL, intramuscular (IM)
Study NCT04220892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) every 3 weeks
Study NCT04220892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
Study NCT04220892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg twice a day, by mouth.
Study NCT00121225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
Study NCT01121406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients receive paclitaxel in a 4 week schedule
Study NCT01121406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients receive gemcitabine in a 3 week schedule
Study NCT01266928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamine C and E
Description: Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
Study NCT03686111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oocytes collect
Description: After stimulation, an echo-guided oocyte puncture is performed under anesthesia
Study NCT03418675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexulti
Description: Atypical antipsychotic
Study NCT03418675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine
Study NCT04162314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-1,3/1,6-D-Glucan Ganoderma lucidum
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Study NCT04162314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study NCT01845415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Marketing Campaign
Description: The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
Study NCT01845415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention components
Description: Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
Study NCT04822909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
Description: The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study
Study NCT02455089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GADD34 RNA level measurement.
Description: Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months.
Study NCT02493855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/ABT-450/Ritonavir
Description: Ombitasvir/ABT-450/ritonavir combination tablets
Study NCT02493855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Dasabuvir tablets
Study NCT02493855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin tablets
Study NCT04097912 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 75-100mg
Study NCT02346916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin
Description: 1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
Study NCT00864513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles